Predictive value of serum cytokine levels in chronic myeloid leukemia patients

Petráčková, Martina; Hamšíková, Eva; Dušková, Martina; Ptáčková, Pavlína; Klamová, Hana; Humlová, Zuzana; Vonka, V.

doi:10.1016/j.imlet.2016.09.004

Cited by 6 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only in the 12th month of observation were the OPT-group patients characterized by higher INF concentrations. This observation is consistent with other reports [26].…”

Section: Discussionsupporting

confidence: 94%

“…In this study, IL8 levels were significantly higher before treatment in patients responding well to treatment, and the result was confirmed in the following months. A study by Petrackova et al supports these observations of positive correlations between plasma IL-8 levels and optimal responses in the course of CML treatment [26]. Our observations are in contrast to the study by Hantschel et al [27], who demonstrated in cell and clinical models that the gene expression of IL-8 is downregulated by dasatinib, and the plasma levels of IL-8 decreased to baseline during imatinib treatment.…”

Section: Discussionsupporting

confidence: 73%

See 1 more Smart Citation

The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity

Janowski,

Łuczkowska,

Gniot

et al. 2024

JCM

View full text Add to dashboard Cite

Background and Objectives: The effective treatment of chronic myeloid leukemia leads to the restoration of proper immune system function. We aimed to investigate fluctuations in circulating cytokines, angiogenic factors and complement components in patients with CML during the first year of treatment with TKI and correlate them with the degree of achieved molecular response. Material and Methods: We recruited 31 patients with newly diagnosed CML. Peripheral blood and bone marrow samples were obtained, and concentrations of serum proteins were measured using an immunology multiplex assay. Results: The study cohort was divided into two groups of optimal or non-optimal in accordance with the European Leukemia Net (ELN) guidelines. We found significantly higher concentrations of C1q, C4 and C5a in serum after 3 months of TKI treatment in patients who achieved optimal responses in the 6 months after diagnosis. The most alterations were observed during 12 months of therapy. Patients in the optimal response group were characterized by higher serum concentrations of TGF-β, EGF, VEGF, Angiopoietin 1, IFN-γ and IL-8. Conclusions: The later plasma concentrations of complement components were significantly increased in patients with optimal responses. The changes after 12 months of treatment were particularly significant. Similar changes in bone marrow samples were observed.

show abstract

“…Only in the 12th month of observation were the OPT-group patients characterized by higher INF concentrations. This observation is consistent with other reports [26].…”

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 73%

The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity

Janowski,

Łuczkowska,

Gniot

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…Serum IL-8 levels were found to be increased in MDS and also in PV and ET, independent of JAK2V617F mutation status ( 118 ). In CML patients, it was reported that high serum IL-8 levels with low serum TGFβ3 could predict treatment outcome better than the traditional Sokal score ( 119 ). In addition, Schinke et al reported that IL-8 and its receptor CXCR2 are expressed at higher levels in pre-LSCs from patients with MDS than in normal human CD34+ cells ( 120 ).…”

Section: Il-8mentioning

confidence: 99%

Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells

2017

View full text Add to dashboard Cite

Hematopoietic stem cells (HSCs) are a rare subset of bone marrow cells that usually exist in a quiescent state, only entering the cell cycle to replenish the blood compartment, thereby limiting the potential for errors in replication. Inflammatory signals that are released in response to environmental stressors, such as infection, trigger active cycling of HSCs. These inflammatory signals can also directly induce HSCs to release cytokines into the bone marrow environment, promoting myeloid differentiation. After stress myelopoiesis is triggered, HSCs require intracellular signaling programs to deactivate this response and return to steady state. Prolonged or excessive exposure to inflammatory cytokines, such as in prolonged infection or in chronic rheumatologic conditions, can lead to continued HSC cycling and eventual HSC loss. This promotes bone marrow failure, and can precipitate preleukemic states or leukemia through the acquisition of genetic and epigenetic changes in HSCs. This can occur through the initiation of clonal hematopoiesis, followed by the emergence preleukemic stem cells (pre-LSCs). In this review, we describe the roles of multiple inflammatory signaling pathways in the generation of pre-LSCs and in progression to myelodysplastic syndrome (MDS), myeloproliferative neoplasms, and acute myeloid leukemia (AML). In AML, activation of some inflammatory signaling pathways can promote the cycling and differentiation of LSCs, and this can be exploited therapeutically. We also discuss the therapeutic potential of modulating inflammatory signaling for the treatment of myeloid malignancies.

show abstract

“…The reason for this variation is likely multifactorial including differences in therapeutic management and effect on hepatic or renal processes [15,17,18]. With respect to hematologic malignancies, this observed variation may also be driven by differences in cytokine expression [21][22][23][24]. Additionally, very few incidences of certain cancers including hairy cell leukemia, multiple myeloma, and breast cancer were observed in our pediatric population which may limit these findings.…”

Section: Discussionmentioning

confidence: 81%

Association between Itch and Cancer in 3836 Pediatric Pruritus Patients at a Tertiary Care Center

et al. 2019

View full text Add to dashboard Cite

Background: Pruritus is a well-recognized paraneoplastic phenomenon. Previous studies have examined the association of itch with a variety of malignancies in adults. However, no large study has examined this association in a pediatric population. Methods: A retrospective study was conducted of patients age 18 or less seen at Johns Hopkins Health System between 2012 and 2019. Results: A pediatric hospital population of 1,042,976 patients was reviewed. Pruritus was observed in 3836 pediatric patients of whom 130 also had cancer. Pediatric patients with pruritus were significantly more likely to have concomitant malignancy compared to pediatric patients without pruritus (OR 12.84; 95% CI 10.73–15.35, p < 0.001). Malignancies most strongly associated with pruritus included neoplasms of the blood (OR 14.38; 95% CI 11.30–18.29, p < 0.001), bone (OR 29.02, 95% CI 18.28–46.06, p < 0.001) and skin (OR 22.76, 95% CI 9.14–56.72, p < 0.001. Conclusions: Pruritus is significantly associated with malignancy in the pediatric hospital population. Clinicians should also be aware of the high burden of itch in pediatric malignancies and the variation in pruritus across malignancies.

show abstract

Predictive value of serum cytokine levels in chronic myeloid leukemia patients

Cited by 6 publications

References 18 publications

The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity

The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity

Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells

Association between Itch and Cancer in 3836 Pediatric Pruritus Patients at a Tertiary Care Center

Contact Info

Product

Resources

About